News • Coronavirus research

Why the Omicron variant causes less severe disease

A new study by researchers from the University of Kent and the Goethe-University Frankfurt shows that the SARS-CoV-2 Omicron variant is less effective than Delta at blocking a cellular defence mechanism against viruses, the so-called 'interferon response'. Moreover, cell culture findings indicate that eight important Covid-19 drugs and drug candidates remain effective against Omicron.

Moreover, cell culture findings indicate that eight important Covid-19 drugs and drug candidates remain effective against Omicron. 

The researchers published their findings in the journal Cell Reports.

Our data provide encouraging evidence that the available antiviral Covid-19 drugs are also effective against Omicron

Jindrich Cinatl

The SARS-CoV-2 Omicron variant causes less severe disease than Delta although it is better at escaping immune protection by vaccinations and previous infections. The reasons for this have so far remained elusive. A new study by a research team with scientists from the University of Kent and the Goethe-University Frankfurt has now shown that Omicron variant viruses are particularly sensitive to inhibition by the so-called interferon response, an unspecific immune response that is present in all body cells. This provides the first explanation of why Covid-19 patients infected with the Omicron variant are less likely to experience severe disease.

The cell culture study also showed that Omicron viruses remain sensitive to eight of the most important antiviral drugs and drug candidates for the treatment of Covid-19. This included 

  • EIDD-1931 (active metabolite of molnupiravir), 
  • ribavirin, 
  • remdesivir, 
  • favipravir, 
  • PF-07321332 (nirmatrelvir, active ingredient of paxlovid), 
  • nafamostat, 
  • camostat, and 
  • aprotinin.

Prof Martin Michaelis, School of Bioscience, University of Kent, said: “Our study provides for the first time an explanation, why Omicron infections are less likely to cause severe disease. Obviously, Omicron can in contrast to Delta not effectively inhibit the host cell interferon immune response.“ 

Prof. Jindrich Cinatl, Institute of Medical Virology at the Goethe-University, added: “Although cell culture experiments do not exactly recapitulate the more complex situation in a patient, our data provide encouraging evidence that the available antiviral Covid-19 drugs are also effective against Omicron.“ 


Source: Goethe-University Frankfurt

25.01.2022

Read all latest stories

Related articles

Photo

News • Anosmia

Loss of smell after Covid-19: Researchers find key reason

After an infection with SARS-CoV-2, some people fail to recover their sense of smell. US researchers took a closer look at the olfactory nerve cells to find the reason for Covid-19-induced anosmia.

Photo

News • First on site, but short-lived

New insights into immune defence may explain Covid-19 reinfections

A new study has found that antibodies produced in the nose decline nine months after Covid-19 infection, while antibodies found in the blood last at least a year.

Photo

News • Answer to SARS-CoV-2 mutations

One step closer to 'variant-proof' Covid-19 vaccine

A vaccine design approach that could protect against new variants of SARS-CoV-2 but also potentially protects against other coronaviruses is one step closer to reality as a result of new research.

Related products

Beckman Coulter – Access Procalcitonin (PCT)

Immunoassays

· Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter Diagnostics
Fujifilm Wako – μTASWako i30

Immunoassays

· Fujifilm Wako – μTASWako i30

FUJIFILM Wako Chemicals Europe GmbH
Mindray – CL-1000i/1200i Chemiluminescence Immunoassay System

Immunoassays

Mindray Medical · Mindray – CL-1000i/1200i Chemiluminescence Immunoassay System

Shenzhen Mindray Bio-Medical Electronics Co., Ltd
Subscribe to Newsletter